Results 121 to 130 of about 188,223 (344)
ClinicoEconomics and Outcomes Research, 2010 Firas Badin, John HayslipUniversity of Kentucky, Markey Cancer Center, Lexington, KY, USAAbstract: Rituximab is an important and well established component in the treatment of many patients with B-cell non-Hodgkin lymphoma. In this paper we review recent
Firas Badin, John Hayslip
doaj
Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: High-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia [PDF]
, 1999 Honghao Yang +2 more
openalex +1 more source
Arthritis &Rheumatology, EarlyView.Objective The objective of this study was to investigate the effect of prophylactic trimethoprim‐sulfamethoxazole (TMP‐SMX) on the incidence of serious infections in patients with antineutrophil cytoplasmic antibody–associated vasculitis (AAV). Methods This multicenter cohort study was designed to emulate a target trial that studied 296 patients with ...
Yun Kyu Kim +7 more
wiley +1 more source
CLONAL SELECTION OF CD20‐NEGATIVE NON‐HODGKIN'S LYMPHOMA CELLS AFTER TREATMENT WITH ANTI‐CD20 ANTIBODY RITUXIMAB [PDF]
, 1999 Katja Schmitz +4 more
openalex +1 more source
Allogeneic hematopoietic cell transplantation as curative therapy for patients with non-Hodgkin lymphoma: Increasingly successful application to older patients [PDF]
, 2016 Non-Hodgkin lymphoma (NHL) constitutes a collection of lymphoproliferative disorders with widely varying biological, histological, and clinical features.
Bredeson, Christopher +9 more
core +2 more sources
Arthritis &Rheumatology, EarlyView.Objective Our objective was to assess the incidence of major adverse cardiovascular events (MACEs) in patients with rheumatoid arthritis (RA) treated with JAK inhibitors (JAKi), tumor necrosis factor inhibitors (TNFi), or biologic disease‐modifying antirheumatic drugs with other modes of action (bDMARD‐OMA) in a multicountry, real‐world population ...
Romain Aymon +28 more
wiley +1 more source
Rituximab Administration in Third Trimester of Pregnancy Suppresses Neonatal B-Cell Development
Clinical and Developmental Immunology, 2008 We describe the effect on the neonate of administration of rituximab to a woman with idiopathic thrombocytopenic purpura (ITP). Rituximab, an anti-CD20 antibody, was given weekly for 4 weeks to a woman with ITP in her third trimester of pregnancy.
D. T. Klink +3 more
doaj +1 more source
Rituximab maintenance therapy: a step forward in follicular lymphoma
Haematologica, 2007 Whilst recent advances in the treatment of follicular lymphoma (FL) have improved the outlook for many patients, relapses still occur and the search continues for strategies to extend the duration of remission without significantly increasing toxicity ...
Marinus H.J. van Oers
doaj +1 more source
, 2014 Primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system is an aggressive malignancy that exhibits unique biological features and characteristic clinical behaviour, with overall long-term survival rates of around 20–40 %.
Cwynarski, K, Fox, CP, Phillips, EH
core +1 more source
Arthritis &Rheumatology, EarlyView.Objective To assess the relationship of circulating and synovial immune cells with synovial molecular pathology and disease outcomes in patients with early rheumatoid arthritis (RA). Methods Patients with early (<12 months) treatment‐naive RA (n = 144) from the Pathobiology of Early Arthritis Cohort were included in this post hoc analysis.
Felice Rivellese +13 more
wiley +1 more source